Showing results (451-460 of 709) with videos related to

Sort By:
Pageof 71
Liver International : Official Journal of the International Association for the Study of the Liver|September 11, 2013
CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell linesFrank Staib, Markus Krupp, Thorsten Maass, et al.
Inflammatory Bowel Diseases|April 3, 2014
Confocal endomicroscopy identifies loss of local barrier function in the duodenum of patients with Crohn's disease and ulcerative colitisLee G Lim, Janina Neumann, Torsten Hansen, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosisChristian Labenz, Michael Nagel, Wolfgang M Kremer, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 20, 2021
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascitesMasatoshi Kudo, Masafumi Ikeda, Peter R Galle, et al.
Digestive Diseases (Basel, Switzerland)|September 24, 2004
Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopyR Kiesslich, S Kanzler, M Vieth, et al.
The Journal of Experimental Medicine|December 8, 1998
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugsM Müller, S Wilder, D Bannasch, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 28, 2012
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenibMarcus A Wörns, Sandra Koch, Ina M Niederle, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 16, 2013
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agentsJens M Kittner, Nora M Weiss, Jörg Wiltink, et al.
Clinical and Translational Gastroenterology|August 9, 2020
Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver CirrhosisWolfgang M Kremer, Michael Nagel, Michael Reuter, et al.
European Journal of Internal Medicine|September 3, 2020
Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosisChristian Labenz, Michael Nagel, Gerrit Toenges, et al.
Pageof 71